Clinical Trials
10 trialsNCT04607772 2025-10-03
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
Karyopharm Therapeutics Inc
Phase 1/2 Withdrawn
NCT05205252 2023-08-15
ARIA
Ipsen
Phase 1/2 Withdrawn
NCT02389543 2023-01-26
SLAM
Karyopharm Therapeutics Inc
Phase 1/2 Withdrawn
NCT04882163 2021-10-05
Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma
Celgene
Phase 1/2 Withdrawn
NCT00829647 2019-04-11
A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia
Scripps Health
Phase 1/2 Withdrawn
NCT03100877 2017-12-13
Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma
City of Hope Medical Center
Phase 1/2 Withdrawn
NCT03191981 2017-08-24
MUKfourteen
University of Leeds
Phase 1/2 Withdrawn
NCT02802163 2017-04-25
Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Withdrawn
NCT02281279 2016-08-11
Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
Mayo Clinic
Phase 1/2 Withdrawn
NCT01180569 2015-09-25
Lenalidomide Therapy In Previously Untreated, Advanced Stage Follicular Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Withdrawn